The goal of this study was to review relevant randomized controlled trials in order to determine the clinical efficacy of golimumab in the treatment of ankylosing spondylitis (AS).
Using appropriate keywords, we identified relevant studies using PubMed, Cochrane and Embase. Key pertinent sources in the literature were also reviewed, and all articles published through November 2019 were considered for inclusion. For each study, we assessed odds ratios, mean difference and 95% confidence interval to assess and synthesize outcomes.
We included nine studies with 6363 patients. Compared with placebo, golimumab would significant decreased the value of BASFI, BASMI, BASDAI, total back pain, JSEQ; increased the value of SF-36 PCS and SF-36 MCS; increased the incidence of BASDAI50, ASAS20, ASAS40 and ASAS partial remission. Compared with golimumab 50 mg, golimumab 100 mg would significantly decreased the value of BASFI and total back pain; increased the value of SF-36 PCS and SF-36 MCS; but also increased the incidence of SAE.
Golimumab had a definite effect in the treatment of AS. The higher dose would obtain better efficacy but lead to the incidence of SAE.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Bath ankylosing spondylitis functional index
Bath ankylosing spondylitis metrology index
Bath ankylosing spondylitis disease activity index
Ankylosing spondylitis disease activity score
Jenkins sleep evaluation questionnaire
Serious adverse event
Food and drug administration
Bao C, Huang F, Khan MA, Fei K, Wu Z, Han C, Hsia EC (2014) Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. Rheumatology (Oxford, England) 53(9):1654–1663. https://doi.org/10.1093/rheumatology/keu132
Braun J, Deodhar A, Inman RD, van der Heijde D, Mack M, Xu S, Hsu B (2012) Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 71(5):661–667. https://doi.org/10.1136/ard.2011.154799
Deodhar A, Braun J, Inman RD, van der Heijde D, Zhou Y, Xu S, Han C, Hsu B (2015) Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis 74(4):757–761. https://doi.org/10.1136/annrheumdis-2014-205862
Deodhar A, Reveille JD, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC (2018) Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE Study. J Rheumatol 45(3):341–348. https://doi.org/10.3899/jrheum.170487
Frampton JE (2017) Golimumab: a review in inflammatory arthritis. BioDrugs: Clin Immunother Biopharm Gene Therapy 31(3):263–274. https://doi.org/10.1007/s40259-017-0217-6
Inman RD, Davis JC Jr, Heijde D, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58(11):3402–3412. https://doi.org/10.1002/art.23969
Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A (2015) Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis 74(3):538–546. https://doi.org/10.1136/annrheumdis-2013-204195
Kruger K, von Hinuber U, Meier F, Tian H, Bohm K, Jugl SM, Borchert K, Meise D, Konig C, Braun S (2018) Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis. Rheumatol Int 38(11):2121–2131. https://doi.org/10.1007/s00296-018-4124-z
Ma H, Sun F, Zhang YM, Zhang H, Zhu J, Deng XH, Zhang JL, Huang F (2017) The safety and efficacy of golimumab in treatment of 25 patients with active ankylosing spondylitis. Zhonghua nei ke za zhi 56(12):935–939. https://doi.org/10.3760/cma.j.issn.0578-1426.2017.12.009
Martinez-Cutillas J, Alerany-Pardo C, Borras-Blasco J, Broto-Sumalla A, Burgos-SanJose A, Climent-Bolta C, Escudero-Vilaplana V, Fernandez-Fuente MA, Ferrit-Martin M, Gomez-Germa P, Martinez-Sesmero JM, Mayorga-Perez J, Menchen-Viso B, Merino-Alonso J, Polache-Vengud J, Sanchez-Guerrero A (2015) The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use. Exp Rev Pharmacoeconomics Outcomes Res 15(5):851–858. https://doi.org/10.1586/14737167.2015.1044514
Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA (2015) TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005468.pub2
Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, Kissling RO, Tamborrini G, Wildi LM, Nissen MJ, Zufferey P, Bernhard J, Weber U, Landewe RBM, van der Heijde D, Ciurea A (2018) TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis 77(1):63–69. https://doi.org/10.1136/annrheumdis-2017-211544
Rahbar MH, Lee M, Hessabi M, Tahanan A, Brown MA, Learch TJ, Diekman LA, Weisman MH, Reveille JD (2018) Harmonization, data management, and statistical issues related to prospective multicenter studies in Ankylosing spondylitis (AS): Experience from the Prospective Study Of Ankylosing Spondylitis (PSOAS) cohort. Contemp Clin Trials Commun 11:127–135. https://doi.org/10.1016/j.conctc.2018.07.004
Stolwijk C, Essers I, van Tubergen A, Boonen A, Bazelier MT, De Bruin ML, de Vries F (2015) The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. Ann Rheum Dis 74(7):1373–1378. https://doi.org/10.1136/annrheumdis-2014-205253
Tam LS, Shang Q, Kun EW, Lee KL, Yip ML, Li M, Li TK, Zhu TY, Pui MO, Li EK, Yu CM (2014) The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis-a randomized, placebo-controlled pilot trial. Rheumatology (Oxford, England) 53(6):1065–1074. https://doi.org/10.1093/rheumatology/ket469
van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany TA, Inman RD, Han C (2014) The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. J Rheumatol 41(6):1095–1103. https://doi.org/10.3899/jrheum.131003
Wang Y, Zheng GQ, Zhang YG, Song K, Song DY, Zhang XS, Wang Z, Lu N, Mao KY (2018) Proposal of a new treatment-oriented classification system for spinal deformity in ankylosing spondylitis. Spine Deform 6(4):366–372. https://doi.org/10.1016/j.jspd.2017.06.001
Wronski J, Fiedor P (2019) The safety profile of tumor necrosis factor inhibitors in ankylosing spondylitis: Are TNF inhibitors safer than we thought? J Clin Pharmacol 59(4):445–462. https://doi.org/10.1002/jcph.1348
Not applicable yet.
Conflict of interest
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Sayed Abdulla, J., Shi, J., Roy, B.S. et al. Patients with ankylosing spondylitis treatment by golimumab: a systematic review and meta-analysis. Eur Spine J 29, 1813–1822 (2020). https://doi.org/10.1007/s00586-020-06466-9
- Ankylosing spondylitis